Track topics on Twitter Track topics that are important to you
Mallinckrodt has agreed to sell its wholly owned subsidiary BioVectra to an affiliate of private equity group H.I.G. Capital for $250 million. The price includes a fixed sum of $175 million, made up of an upfront payment of $135 million plus a long-term note for $40 million, as well as contingent payments of up to $75 million.
Original Article: Mallinckrodt Sells BioVectra to H.I.G. CapitalNEXT ARTICLE